Editas Medicine Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EDIT Nasdaq 2836 https://www.editasmedicine.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Editas Medicine Inc

Why Editas Medicine Stock Is Soaring Today - Sep 29th, 2023 3:21 pm
The Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan - Sep 28th, 2023 10:27 am
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer - Sep 25th, 2023 8:30 pm
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer - Sep 25th, 2023 1:00 pm
1 Gene Editing Stock to Buy Now, and 1 to Sell - Sep 23rd, 2023 12:45 pm
Ultragenyx (RARE) Soars 6.1%: Is Further Upside Left in the Stock? - Sep 8th, 2023 9:03 am
Ligand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound? - Sep 7th, 2023 3:30 pm
Why Is Editas (EDIT) Down 4.3% Since Last Earnings Report? - Sep 1st, 2023 3:31 pm
Editas Medicine Announces Upcoming Investor Events - Aug 30th, 2023 1:00 pm
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer - Aug 28th, 2023 11:00 am
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street - Aug 23rd, 2023 12:25 pm
Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript - Aug 4th, 2023 4:38 pm
Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus - Aug 3rd, 2023 3:45 pm
Editas Medicine (EDIT) Reports Q2 Loss, Misses Revenue Estimates - Aug 2nd, 2023 12:25 pm
Editas Medicine Announces Second Quarter 2023 Results and Business Updates - Aug 2nd, 2023 11:00 am
The past three years for Editas Medicine (NASDAQ:EDIT) investors has not been profitable - Jul 31st, 2023 11:02 am
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization - Jul 27th, 2023 1:00 pm
The Petri Dish: Pfizer ends Syros collab; Editas hires 37-year Biogen vet - Jul 27th, 2023 10:29 am
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update - Jul 26th, 2023 11:00 am